SCHEMBL4146232

SCHEMBL4146232

Nc1ccnc2ccc(-c3cccc4[nH]ccc34)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 3/20 0.51
PIK3CB P42338 2/20 0.51
PIK3CG P48736 1/20 0.51
ASH1L Q9NR48 1/20 0.48
ACVR1 Q04771 2/20 0.44
IRAK4 Q9NWZ3 1/20 0.43
NR4A2 P43354 1/20 0.43
PRKCI P41743 2/20 0.43
CSNK2B P67870 1/20 0.42
CSNK2A1 P68400 1/20 0.42
CHEK1 O14757 1/20 0.42
DHFR P00374 1/20 0.42
CCNK O75909 1/20 0.41
CDK12 Q9NYV4 1/20 0.41
NCF1 P14598 1/20 0.41
ABL1 P00519 1/20 0.40
PIP4K2A P48426 1/20 0.40
PIP4K2B P78356 1/20 0.40
PIP4K2C Q8TBX8 1/20 0.40
AURKA O14965 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4147845 0.77 MAP3K11 (0.48) PIK3CDPIK3CGIRAK4NR4A2
SCHEMBL4151014 0.77 NR4A2 (0.46) PIK3CDPIK3CBPIK3CGNR4A2PRKCI
SCHEMBL21318581 0.76 CYP1A2 (0.62) PIK3CDPIK3CBPIK3CGIRAK4RAF1
SCHEMBL3359926 0.74 JAK2 (0.59) PIK3CDPIK3CBPIK3CGASH1LCSNK2B
SCHEMBL16459814 0.72 NR4A2 (0.55) PIK3CDPIK3CBPIK3CGACVR1NR4A2
SCHEMBL982028 0.72 ASH1L (0.63) PIK3CDPIK3CBPIK3CGASH1LCSNK2B
SCHEMBL5830148 0.72 PIK3CD (0.55) PIK3CDPIK3CBPIK3CGASH1LCSNK2B
SCHEMBL31456259 0.71 PIK3CD (0.58) PIK3CDPIK3CBPIK3CGASH1LCSNK2B
SCHEMBL5830444 0.71 PIK3CD (0.58) PIK3CDPIK3CBPIK3CGASH1LCSNK2B
SCHEMBL12281648 0.71 DYRK1B (0.73) IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069338-A1 Method for predicting skin sensitizing activity of compounds DICKSON JR JOHN K 2009-03-12 US disclosed
US-7452887-B2 Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof AMPHORA DISCOVERY CORPORATION (US) 2008-11-18 US disclosed
US-20060009460-A1 Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof AGRIUS GROUP, LLC. 2006-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069338-A1 Method for predicting skin sensitizing activity of compounds ATP5ME, ABCG2, ATP5MG PIK3CD 1049/4885PIK3CB 572/4885PIK3CG 964/4885
US-20060009460-A1 Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof ATP5ME, ATP5MG, ATP5MK PIK3CD 379/4885PIK3CB 283/4885PIK3CG 356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.